Pictet Asset Management (Switzerland)’s Arcutis Biotherapeutics ARQT Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$12.6M	Sell	1,327,029 -329,036	-20%	-$3.65M	0.02%	572
2023 Q1	$18.2M	Buy	1,656,065 +17,132	+1%	+$248K	0.02%	485
2022 Q4	$24.3M	Buy	1,638,933 +36,147	+2%	+$632K	0.04%	406
2022 Q3	$30.6M	Buy	1,602,786 +679,892	+74%	+$15.4M	0.05%	349
2022 Q2	$19.7M	Buy	+922,894	New	+$18.9M	0.03%	464

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ARQT Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Arcutis Biotherapeutics (ARQT) stake by 20% in Q2 2023, selling an estimated $3.65M and leaving 1,327,029 shares worth $12.6M. The position accounts for 0.02% of the portfolio, ranked #572.

Pictet Asset Management (Switzerland) first reported a position in ARQT in Q2 2022 and has held it in 5 quarters since. The position peaked at $30.6M in Q3 2022. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,327,029 shares of Arcutis Biotherapeutics worth $12.6M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 329,036 Arcutis Biotherapeutics shares in Q2 2023, an estimated $3.65M.
Arcutis Biotherapeutics made up 0.02% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #572 holding.
Pictet Asset Management (Switzerland) first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 5 quarters since.
Pictet Asset Management (Switzerland)'s Arcutis Biotherapeutics position peaked at $30.6M in Q3 2022.
136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.